

\$2.6m in non-dilutive capital secured to fast track TRP-8803 clinical development

- Agreement with Rockford Equity Pty Ltd to provide a line of credit against eligible FY26 R&D expenditure
- Strengthens existing cash reserves of \$3.03m (as at 30 June 2025) and pending FY24 \$800,000 R&D Tax Incentive expected to be received this quarter
- Non-dilutive capital provides financial flexibility to fast-track TYP's world-first trial using TRP-8803 (IV-infused psilocin) in Binge Eating Disorder (BED) and additional clinical trial opportunities

Melbourne, Australia – Tryptamine Therapeutics Limited ('Tryp', 'TYP' or the 'Company') (ASX: TYP), a clinical-stage biotechnology company, is pleased to announce it has entered into an R&D loan facility agreement with Rockford Equity Pty Ltd ('Rockford').

The facility is secured against the Company's projected FY26 research and development activities, which totals \$2.6m and will be repaid from Tryp's future R&D Tax Incentive ("RDTI"). The Company can elect to drawdown on the facility in \$500,000 tranches and will accrue interest at 16% per annum on the outstanding balance.

The agreement considerably strengthens the Company's existing cash position of \$3.03m at 30 June 2025 (ASX announcement: 31 July 2025). This is expected to be bolstered by an ATO R&D tax rebate in the coming months of ~\$800,000 for eligible FY24 activities.

This new capital provides additional non-dilutive funding as the Company advances clinical development of TRP-8803 (IV-infused psilocin), as well as its broader clinical activities. This includes the Company's world-first clinical trial with Swinburne University to assess the safety and efficacy of TRP-8803 for adult patients with BED (ASX announcement: 10 April 2025), as well as other pending trial developments.

Management commentary:

Tryp Chief Executive Officer, Jason Carroll, said: *"We are pleased to have executed this agreement with Rockford, which provides the Company with financial flexibility at a pivotal time in development of lead asset, TRP-8803. The capital, if required will be used towards fast tracking a number of key development milestones, including our trial into BED with Swinburne, as well as other opportunities which are very well advanced. I look forward to providing further updates on these developments in the near term."*

This announcement has been authorised for release by the Board of Tryptamine Therapeutics Limited.

-ENDS-

About Tryptamine Therapeutics Limited

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to



onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder at the University of Florida, which demonstrated an average reduction in binge eating episodes of greater than 80%.

The Company also has also just completed a Phase 2a clinical trial for the treatment of fibromyalgia in collaboration with the University of Michigan and has initiated a Phase 2a clinical trial in collaboration with Massachusetts General Hospital for the treatment of abdominal pain and visceral tenderness in patients suffering from irritable bowel syndrome.

Each of the studies is utilising TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications. Where a positive clinical response is demonstrated, subsequent studies are expected to utilise TRP-8803 (IV-infused psilocin), that has the potential to further improve efficacy, safety, and patient experience.

For more information, please visit www.tryptherapeutics.com.

Investor & Media Contact

Jason Carroll
Chief Executive Officer
Tryptamine Therapeutics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release, constitutes forward looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's Replacement Prospectus available at www.asx.com.au These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.